Fundz

Imago Bio Sciences, Inc. reported raising $17 Million in an initial SEC Form D filing, from an offering of $40 Million

PRIVATEMar 28, 2019$17M of $40M raised

Amount Raised

$17 Million

$17 Million sold, per SEC Form D (first sale Mar 28, 2019)

Round Type

Venture

San CarlosBiotechnologyHealthcareHealth CareTherapeuticsPharmaceutical

Quick answer

Imago BioSciences, Inc. raised $17 Million in a funding round, dated March 28, 2019. Imago BioSciences, Inc. is based in San Carlos, California, United States.

How much did Imago BioSciences, Inc. raise?
Imago BioSciences, Inc. raised $17 Million in a funding round on March 28, 2019.
What does Imago BioSciences, Inc. do?
Imago BioSciences is a clinical-stage biopharmaceutical company discovering and developing novel small molecule product candidates that target lysine-specific demethylase 1 (LSD1), an enzyme that plays a central role in..
Where is Imago BioSciences, Inc. based and how big is it?
Imago BioSciences, Inc. is based in San Carlos, California, United States.

Source: Fundz verified event record.

Who else raised in Healthcare and Therapeutics around the same time

Companies in the same sectors as Imago BioSciences, Inc. that raised within 45 days of this round, from Fundz verified event records.

  • MBX Biosciences, Inc. raised $23M on May 10, 2019.
  • Oncotelic Therapeutics raised $27M on May 7, 2019.
  • Oncotelic Therapeutics raised $600K (Seed) on May 7, 2019.
  • DTx Pharma, Inc. raised $5.5M on April 23, 2019.
  • Korsana Biosciences raised $175M on April 17, 2019.
  • valisure llc raised $853K (Seed) on April 10, 2019.

Who to call at Imago BioSciences, Inc., and when

A new round usually means Imago BioSciences, Inc. is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Imago BioSciences, Inc. raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Imago BioSciences, Inc., from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Imago BioSciences, Inc.. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Imago BioSciences, Inc.

Location

2729 Debbie Court

San Carlos, California, United States

About

Imago BioSciences is a clinical-stage biopharmaceutical company discovering and developing novel small molecule product candidates that target lysine-specific demethylase 1 (LSD1), an enzyme that plays a central role in the production of blood cells in the bone marrow. Imago is focused on improving the quality and length of life for patients with cancer and bone marrow diseases. Bomedemstat, an orally available, small molecule inhibitor of LSD1, is the lead product candidate discovered by Imago for the treatment of certain myeloproliferative neoplasms (MPNs), a family of related, chronic cancers of the bone marrow. Imago is evaluating Bomedemstat as a potentially disease-modifying therapy in two Phase 2 clinical trials for the treatment of essential thrombocythemia (NCT04254978) and myelofibrosis (NCT03136185). Bomedemstat has U.S. FDA Orphan Drug and Fast Track Designation for the treatment of ET and MF, European Medicines Agency (EMA) Orphan Designation for the treatment of ET and MF, and PRIority MEdicines (PRIME) Designation by the EMA for the treatment of MF. Imago is based in Redwood City, California. To learn more, visit www.imagobio.com, myelofibrosisclinicalstudy.com, www.etclinicalstudy.com and follow us on Twitter @ImagoBioRx, Facebook and LinkedIn.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Imago BioSciences, Inc. raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Imago BioSciences, Inc.'s next move

See what Strategic adds

Imago BioSciences, Inc. raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.